Association between medical androgen deprivation therapy and long‐term cardiovascular disease and all‐cause mortality in nonmetastatic prostate cancer

Forster, Rachel; Engeland, Anders; Kvåle, Rune; Hjellvik, Vidar; Björge, Tone

doi:10.1002/ijc.34058

Cited by 11 publications

(10 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The preva-lence of several drugs was higher in CRC-survivors than in the cancer-free population ten years after diagnosis, especially drugs for gastric acid disorder and pain medications (29). Among non-metastatic prostate cancer patients hormonal treatment was associated with an increased risk of cardiovascular disease (CVD) events, especially in patients with some CVD risk factors present at the time of their diagnosis and longer duration of treatment (30). We also found higher allcause mortality among patients receiving hormonal therapy.…”

Section: Long-term Adverse Health Effects In Cancer Patients: Prescri...mentioning

confidence: 65%

See 1 more Smart Citation

The Cancer Registry of Norway – “a ground for scientific harvesting”

Engeland¹,

Nystad²,

Selmer³

2022

Nor J Epidemiol

Self Cite

View full text Add to dashboard Cite

The Cancer Registry of Norway (CRN) has been important in registry-based research in Norway for decades. The use of CRN in combination with other population-based registries and health surveys have been the basis for numerous research projects, which has contributed to fill important knowledge gaps. Researchers at the Norwegian Institute of Public Health and CRN have a long tradition of using these data sources to address research questions of common interests such as e.g. the effect of life style and diet on cancer risk. CRN and the Medical Birth Registry of Norway have co-existed for a long period, making it possible to study cancer incidence and birth characteristics over generations. During the last decades, several new registries such as the Norwegian Prescription Database and the Norwegian Patient Registry have been established, providing opportunities for studying for example drug use and cancer risk and the influence of comorbidities on the development of cancer. In the future, the CRN will be an even more valuable data source when also other population-based registries and health surveys have existed for longer time periods.

show abstract

Section: Long-term Adverse Health Effects In Cancer Patients: Prescri...mentioning

confidence: 65%

“…Studies on drug use in survivors of colorectal and prostate cancer have been published (29,30). The preva-lence of several drugs was higher in CRC-survivors than in the cancer-free population ten years after diagnosis, especially drugs for gastric acid disorder and pain medications (29).…”

Section: Long-term Adverse Health Effects In Cancer Patients: Prescri...mentioning

confidence: 99%

The Cancer Registry of Norway – “a ground for scientific harvesting”

Engeland¹,

Nystad²,

Selmer³

2022

Nor J Epidemiol

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, the use of gonadotropin-releasing hormone (or androgen blockers) as a pharmacological androgen deprivation therapy (ADT) is considered highly effective in cis-men experiencing metastatic prostate cancer. Numerous studies indicate that ADT used to treat cis-men with prostate cancer is associated with adverse cardiovascular events that can lead to significant morbidity, 58,59 along with increased incidence of coronary heart disease, myocardial infarction, and sudden cardiac death. 60 ADT in cis-men is also associated with increased body weight and fat mass and a decrease in lean mass, [61][62][63][64] insulin resistance, 65 glucose intolerance, 66 diabetes, 60,67 and changes in lipid profiles (increased total cholesterol, non-HDL cholesterol, and LDL cholesterol).…”

Section: Gaht To Reduce Biological Effects Of Androgens In Twmentioning

confidence: 99%

Insights Into the Cardiomodulatory Effects of Sex Hormones: Implications in Transgender Care

et al. 2023

View full text Add to dashboard Cite

Transgender individuals that undergo gender-affirming hormone therapy may experience discrimination in the health care setting with a lack of access to medical personnel competent in transgender medicine. Recent evidence suggests that gender-affirming hormone therapy is associated with an increased risk of cardiovascular diseases and cardiovascular risk factors. A recent statement from the American Heart Association reinforces the importance of cardiovascular-focused clinical management and the necessity for more research into the impact of gender-affirming hormone therapy. With this in mind, this review will highlight the known cardiovascular risk factors associated with gender-affirming hormone therapy and identify potential molecular mechanisms determined from the limited animal studies that explore the role of cross-sex steroids on cardiovascular risk. The lack of data in this understudied population requires future clinical and basic research studies to inform and educate clinicians and their transgender patient population to promote precision medicine for their care to improve their quality of life.

show abstract

“…Therefore, how to prevent death from CVD in cancer survivors is a question worth exploring. Although several studies have addressed this field, they mainly focused on breast, colorectal, prostate, and other cancers[ 16 - 18 ], and studies focusing on CVD outcomes in HCC patients have not been reported.…”

Section: Introductionmentioning

confidence: 99%

Risk of cardiovascular death in patients with hepatocellular carcinoma based on the Fine-Gray model

Zhang,

Liu,

Liu

et al. 2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

BACKGROUND Hepatocellular carcinoma (HCC) is one of the most common types of cancers worldwide, ranking fifth among men and seventh among women, resulting in more than 7 million deaths annually. With the development of medical technology, the 5-year survival rate of HCC patients can be increased to 70%. However, HCC patients are often at increased risk of cardiovascular disease (CVD) death due to exposure to potentially cardiotoxic treatments compared with non-HCC patients. Moreover, CVD and cancer have become major disease burdens worldwide. Thus, further research is needed to lessen the risk of CVD death in HCC patient survivors. AIM To determine the independent risk factors for CVD death in HCC patients and predict cardiovascular mortality (CVM) in HCC patients. METHODS This study was conducted on the basis of the Surveillance, Epidemiology, and End Results database and included HCC patients with a diagnosis period from 2010 to 2015. The independent risk factors were identified using the Fine-Gray model. A nomograph was constructed to predict the CVM in HCC patients. The nomograph performance was measured using Harrell’s concordance index (C-index), calibration curve, receiver operating characteristic (ROC) curve, and area under the ROC curve (AUC) value. Moreover, the net benefit was estimated via decision curve analysis (DCA). RESULTS The study included 21545 HCC patients, of whom 619 died of CVD. Age (< 60) [1.981 (1.573-2.496), P < 0.001], marital status (married) [unmarried: 1.370 (1.076-1.745), P = 0.011], alpha fetoprotein (normal) [0.778 (0.640-0.946), P = 0.012], tumor size (≤ 2 cm) [(2, 5] cm: 1.420 (1.060-1.903), P = 0.019; > 5 cm: 2.090 (1.543-2.830), P < 0.001], surgery (no) [0.376 (0.297-0.476), P < 0.001], and chemotherapy(none/unknown) [0.578 (0.472-0.709), P < 0.001] were independent risk factors for CVD death in HCC patients. The discrimination and calibration of the nomograph were better. The C-index values for the training and validation sets were 0.736 and 0.665, respectively. The AUC values of the ROC curves at 2, 4, and 6 years were 0.702, 0.725, 0.740 in the training set and 0.697, 0.710, 0.744 in the validation set, respectively. The calibration curves showed that the predicted probabilities of the CVM prediction model in the training set vs the validation set were largely consistent with the actual probabilities. DCA demonstrated that the prediction model has a high net benefit. CONCLUSION Risk factors for CVD death in HCC patients were investigated for the first time. The nomograph served as an important reference tool for relevant clinical management decisions.

show abstract

Association between medical androgen deprivation therapy and long‐term cardiovascular disease and all‐cause mortality in nonmetastatic prostate cancer

Cited by 11 publications

References 50 publications

The Cancer Registry of Norway – “a ground for scientific harvesting”

The Cancer Registry of Norway – “a ground for scientific harvesting”

Insights Into the Cardiomodulatory Effects of Sex Hormones: Implications in Transgender Care

Risk of cardiovascular death in patients with hepatocellular carcinoma based on the Fine-Gray model

Contact Info

Product

Resources

About